STORM in the News
Scrip Intelligence: STORM’s METTL3 Inhibitor Effective Against AML
Emerging Company Profile: STORM Therapeutics publishes data in Nature showing its first-in-class inhibitor of METTL3 is effective as a new therapeutic strategy against AML
To read the full article, please click here